Cargando…

miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2

It has been well documented that miRNAs can modulate the effectiveness of cancer-associated signaling pathways. Mitogen-activated protein kinase (MAPK/ERK) signaling plays an essential role in the progression of many cancers, including melanoma and colon cancers. However, no single miRNA is reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Szu-Mam, Lu, Jean, Lee, Hoong-Chien, Chung, Feng-Hsiang, Ma, Nianhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253445/
https://www.ncbi.nlm.nih.gov/pubmed/25275294
_version_ 1782347259710537728
author Liu, Szu-Mam
Lu, Jean
Lee, Hoong-Chien
Chung, Feng-Hsiang
Ma, Nianhan
author_facet Liu, Szu-Mam
Lu, Jean
Lee, Hoong-Chien
Chung, Feng-Hsiang
Ma, Nianhan
author_sort Liu, Szu-Mam
collection PubMed
description It has been well documented that miRNAs can modulate the effectiveness of cancer-associated signaling pathways. Mitogen-activated protein kinase (MAPK/ERK) signaling plays an essential role in the progression of many cancers, including melanoma and colon cancers. However, no single miRNA is reported to directly target multiple components of the MAPK/ERK pathway. We performed a miRNA PCR array screening with various MAPK/ERK signaling activities. The miRNA array data revealed that the expression of miR-524-5p was decreased in cells with an active MAPK/ERK pathway and confirmed that the expression of miR-524-5p is inversely associated with the activity of the MAPK/ERK pathway. We demonstrated that miR-524-5p directly binds to the 3′-untranslated regions of both BRAFandERK2 and suppresses the expression of these proteins. Because BRAF and ERK2 are the main components of MAPK signaling, the overexpression of miR-524-5p effectively inhibits MAPK/ERK signaling, tumor proliferation, and melanoma cell migration. Moreover, tumors overexpressing miR-524-5p were significantly smaller than those of the negative control mice. Our findings provide new insight into the role of miR-524-5p as an important miRNA that negatively regulates the MAPK/ERK signaling pathway, suggesting that miR-524-5p could be a potent therapeutic candidate for melanoma treatment.
format Online
Article
Text
id pubmed-4253445
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-42534452014-12-03 miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2 Liu, Szu-Mam Lu, Jean Lee, Hoong-Chien Chung, Feng-Hsiang Ma, Nianhan Oncotarget Research Paper It has been well documented that miRNAs can modulate the effectiveness of cancer-associated signaling pathways. Mitogen-activated protein kinase (MAPK/ERK) signaling plays an essential role in the progression of many cancers, including melanoma and colon cancers. However, no single miRNA is reported to directly target multiple components of the MAPK/ERK pathway. We performed a miRNA PCR array screening with various MAPK/ERK signaling activities. The miRNA array data revealed that the expression of miR-524-5p was decreased in cells with an active MAPK/ERK pathway and confirmed that the expression of miR-524-5p is inversely associated with the activity of the MAPK/ERK pathway. We demonstrated that miR-524-5p directly binds to the 3′-untranslated regions of both BRAFandERK2 and suppresses the expression of these proteins. Because BRAF and ERK2 are the main components of MAPK signaling, the overexpression of miR-524-5p effectively inhibits MAPK/ERK signaling, tumor proliferation, and melanoma cell migration. Moreover, tumors overexpressing miR-524-5p were significantly smaller than those of the negative control mice. Our findings provide new insight into the role of miR-524-5p as an important miRNA that negatively regulates the MAPK/ERK signaling pathway, suggesting that miR-524-5p could be a potent therapeutic candidate for melanoma treatment. Impact Journals LLC 2014-09-08 /pmc/articles/PMC4253445/ /pubmed/25275294 Text en Copyright: © 2014 Liu et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Liu, Szu-Mam
Lu, Jean
Lee, Hoong-Chien
Chung, Feng-Hsiang
Ma, Nianhan
miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
title miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
title_full miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
title_fullStr miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
title_full_unstemmed miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
title_short miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
title_sort mir-524-5p suppresses the growth of oncogenic braf melanoma by targeting braf and erk2
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253445/
https://www.ncbi.nlm.nih.gov/pubmed/25275294
work_keys_str_mv AT liuszumam mir5245psuppressesthegrowthofoncogenicbrafmelanomabytargetingbrafanderk2
AT lujean mir5245psuppressesthegrowthofoncogenicbrafmelanomabytargetingbrafanderk2
AT leehoongchien mir5245psuppressesthegrowthofoncogenicbrafmelanomabytargetingbrafanderk2
AT chungfenghsiang mir5245psuppressesthegrowthofoncogenicbrafmelanomabytargetingbrafanderk2
AT manianhan mir5245psuppressesthegrowthofoncogenicbrafmelanomabytargetingbrafanderk2